Skip to main content
. 2021 Sep 17;44(11):2573–2581. doi: 10.2337/dc21-1170

Figure 2.

Figure 2

Treatment effect of dapagliflozin by risk category predicted by the biomarker-based risk score. ARR was calculated by subtracting the Kaplan-Meier event rates for HHF at 4 years in patients treated with dapagliflozin from the Kaplan-Meier event rates for HHF at 4 years in patients treated with placebo across each risk score category. There was a significant gradient of increasing ARR with increasing risk category.